133 related articles for article (PubMed ID: 37766811)
1. Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective.
Hansen DK; Bixby T; Fixler K; Shea L; Brittle C; Brunisholz K; Liu YH; Huo JS
J Patient Exp; 2023; 10():23743735231202733. PubMed ID: 37766811
[TBL] [Abstract][Full Text] [Related]
2. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.
Owattanapanich W; Suphadirekkul K; Kunacheewa C; Ungprasert P; Prayongratana K
BMC Cancer; 2018 Nov; 18(1):1126. PubMed ID: 30445930
[TBL] [Abstract][Full Text] [Related]
3. The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation.
Martino M; Pitino A; Tripepi G; Paviglianiti A; Russo L; Cusumano G; Rossetti A; Provenzano PF; Porto G; Meliambro N; Gallo S; Porcino D; Romeo V; Gangemi T; D'Arrigo G; Imbalzano L; Console G; Gori M
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e402-e409. PubMed ID: 33288484
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.
Lyall M; Crawford R; Bell T; Mamolo C; Neuhof A; Levy C; Heyes A
JMIR Cancer; 2022 Sep; 8(3):e39068. PubMed ID: 36136395
[TBL] [Abstract][Full Text] [Related]
5. Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes.
Ebraheem MS; Seow H; Balitsky AK; Pond GR; Wildes TM; Sivapathasundaram B; Sussman J; Mian H
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e714-e721. PubMed ID: 34099429
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
8. Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma.
Khouri J; Majhail NS
Curr Opin Support Palliat Care; 2017 Dec; 11(4):361-365. PubMed ID: 28922292
[TBL] [Abstract][Full Text] [Related]
9. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
[TBL] [Abstract][Full Text] [Related]
11. Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT; Lonial S; Nooka AK
Transplant Cell Ther; 2022 Feb; 28(2):75.e1-75.e7. PubMed ID: 34626863
[TBL] [Abstract][Full Text] [Related]
12. Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis.
Mian O; Puts M; McCurdy A; Wildes TM; Fiala MA; Kang M; Salib M; Alibhai S; Mian H
Front Oncol; 2022; 12():974038. PubMed ID: 36776355
[TBL] [Abstract][Full Text] [Related]
13. Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single-centre, retrospective review in the Australian setting.
Tan XN; Yew CY; Ragg SJ; Harrup RA; Johnston AM
Intern Med J; 2022 Jul; 52(7):1242-1250. PubMed ID: 33949777
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
Holstein SA; Suman VJ; Owzar K; Santo K; Benson DM; Shea TC; Martin T; Silverman M; Isola L; Vij R; Cheson BD; Linker C; Anderson KC; Richardson PG; McCarthy PL
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1414-1424. PubMed ID: 32325171
[TBL] [Abstract][Full Text] [Related]
16. Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation.
Mohyuddin GR; Abbasi S; Okoniewski M; McClune B; Abdallah AO; Ganguly S; McGuirk J; Shune L
Eur J Haematol; 2020 Nov; 105(5):571-577. PubMed ID: 32662224
[TBL] [Abstract][Full Text] [Related]
17. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
Liu J; Yan W; Fan H; Xu J; Li L; Du C; Mao X; Yan Y; Xu Y; Sui W; Deng S; Yi S; Anderson KC; Qiu L; Zou D; An G
Cancer Res Commun; 2023 Sep; 3(9):1770-1780. PubMed ID: 37680953
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for Catheter-Related Thrombosis in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Hoppe A; Rupa-Matysek J; Małecki B; Dytfeld D; Hoppe K; Gil L
Medicina (Kaunas); 2021 Sep; 57(10):. PubMed ID: 34684057
[No Abstract] [Full Text] [Related]
19. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.
Kansagra A; Gonsalves WI; Gertz MA; Buadi FK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Kapoor P; Muchtar E; Kourelis TV; Warsame R; Leung N; Zeldenrust SR; Lust JA; Rajkumar SV; Kyle RA; Hogan W; Kumar SK
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2127-2132. PubMed ID: 29656139
[TBL] [Abstract][Full Text] [Related]
20. The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study.
Camilleri M; Bekris G; Sidhu G; Buck C; Elsden E; McCourt O; Horder J; Newrick F; Lecat C; Sive J; Papanikolaou X; Popat R; Lee L; Xu K; Kyriakou C; Rabin N; Yong K; Fisher A
Support Care Cancer; 2022 Sep; 30(9):7469-7479. PubMed ID: 35657402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
